

UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF NEW YORK

USDC SDNY  
DOCUMENT  
ELECTRONICALLY FILED  
DOC #:  
DATE FILED: 2/12/09

-----X  
:  
TAKEDA CHEMICAL INDUSTRIES, LTD. and  
TAKEDA PHARMACEUTICALS NORTH AMERICA,  
INC.,

Plaintiffs,

-v-

WATSON PHARMACEUTICALS, ET AL.,  
Defendants.  
-----X

03 Civ. 8254 (DLC)

ORDER

DENISE COTE, DISTRICT JUDGE:


The above-captioned matter is related to five other cases brought by plaintiffs Takeda Chemical Industries, Ltd. and Takeda Pharmaceuticals of North America, Inc. alleging infringement of combination-use patents involving the compound pioglitazone. Four of the related cases, Takeda Chemical Industries, Ltd. and Takeda Pharmaceuticals of North America, Inc. v. Ranbaxy Laboratories Ltd. and Ranbaxy Pharmaceuticals, Inc., No. 03 Civ. 8250; Takeda Chemical Industries, Ltd. and Takeda Pharmaceuticals of North America, Inc. v. Mylan Laboratories Inc., et al., No. 03 Civ. 8253; Takeda Chemical Industries, Ltd. and Takeda Pharmaceuticals of North America, Inc. v. Watson Pharmaceuticals, et al., No. 03 Civ. 8254; and Takeda Chemical Industries, Ltd. and Takeda Pharmaceuticals of North America, Inc. v. AlphaPharm Pty., Ltd. and Genpharm, Inc., No. 04 Civ. 1966, were stayed by an Order of March 7, 2006 until

the submission of a status letter due January 9, 2009. An Opinion and Order dated October 9, 2007 stayed a related matter, Takeda Chemical Industries, Ltd. and Takeda Pharmaceuticals of North America, Inc. v. Sandoz, Inc., No. 07 Civ. 3844, also until the submission of a status letter due January 9, 2009. At a conference held on October 3, 2008 to discuss a more recently filed related case, Takeda Chemical Industries, Ltd., et al. v. Mylan, Inc., et al., No. 08 Civ. 6999, that matter was also stayed until the submission of a status letter due January 9, 2009.<sup>1</sup> Status letters have been received and a conference was held on the record on February 5, 2009. Accordingly, it is hereby

ORDERED that the stay of litigation regarding Takeda's claims of infringement of its pioglitazone combination-use patents is lifted.

SO ORDERED.

Dated: New York, New York  
February 12, 2009

  
\_\_\_\_\_  
DENISE COTE  
United States District Judge

---

<sup>1</sup> In addition to Takeda Chemical Industries, Ltd. and Takeda Pharmaceuticals of North America, Inc., this action includes as a plaintiff Takeda Global Research and Development Center, Inc.